Tag: Recurrent ovarian cancer options

Home / Recurrent ovarian cancer options

Categories

Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, ...
recurrent-ovarian-cancer-options

Scan the code